These findings indicate that CD11c+CD8+ T cells may have potential anti-tumor activity and that GB+CD11c+CD8+ T cells are associated with disease progression in patients with HBV-related HCC. This evidence concerns the gene ITGAX and hepatocellular carcinoma.